drugset / Trial / NCT02416271

The Forteo Alendronate Comparator Trial

NCT02416271

Phase 4 Completed 203 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to evaluate the effects of teriparatide with those of alendronate on spine bone mineral density (BMD) and other osteoporosis factors in postmenopausal women with osteoporosis.

Timeline

Start
2001-04
Primary completion
2003-05
Completion
2003-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alendronic Acid Small molecule 10 mg Oral
Subject Teriparatide Protein / enzyme biologic 20 ug Subcutaneous

Indications